Results 1 to 10 of about 743 (109)
Epilepsia Open, 2020 Objective To evaluate the success of initiation of adjunctive brivaracetam in patients who required a change in antiepileptic drug (AED) regimen and substituted at least one AED with brivaracetam.
Holger Lerche +7 more
doaj +2 more sources
Overnight switch from levetiracetam to brivaracetam. Safety and tolerability [PDF]
Epilepsy & Behavior Reports, 2021 Brivaracetam is a newer antiseizure medication than levetiracetam. It has a more selective action on the synaptic vesicle glycoprotein 2A binding site, and it seems to provide a more favorable neuropsychiatric profile. The aim of this study was to assess
L. Abraira +6 more
doaj +2 more sources
Brivaracetam attenuates pain behaviors in a murine model of neuropathic pain
Molecular Pain, 2019 Background The antiseizure racetams may provide novel molecular insights into neuropathic pain due to their unique mechanism involving synaptic vesicle glycoprotein 2A.
Solomiya Tsymbalyuk +7 more
doaj +3 more sources
Brivaracetam: A Novel Antiepileptic Drug for Focal-Onset Seizures
Therapeutic Advances in Neurological Disorders, 2018 Brivaracetam (BRV), the n -propyl analogue of levetiracetam (LEV), is the latest antiepileptic drug (AED) to be licensed in Europe and the USA for the adjunctive treatment of focal-onset seizures with or without secondary generalization in patients aged ...
Linda J Stephen, Martin J Brodie
exaly +2 more sources
Эпилепсия и пароксизмальные состояния, 2023 The review considers pharmacological characteristics of new antiepileptic drugs (AEDs) of the third generation such as eslicarbazepine, lacosamide, retigabine, perampanel, everolimus, brivaracetam, zonisamide.
Z. G. Tadtaeva +3 more
doaj +1 more source
Pharmaceuticals, 2021 Brivaracetam (BRV) is the latest approved antiepileptic drug. The aim of the study was to evaluate the efficacy and tolerability of BRV in everyday clinical practice.
Maria Stefanatou +11 more
doaj +1 more source
EFFICACY OF BRIVARACETAM IN PEDIATRIC EPILEPSY: AN UP-TO-DATE [PDF]
Euromediterranean Biomedical Journal, 2021 Among the newest antiepileptic drugs, brivaracetam (BRV), previously known as “ucb34714”, is one of the most interesting molecules available, increasingly getting the attention of researchers.
Antonio Nicotera
doaj +1 more source
Biomedicines, 2021 Brivaracetam (BRV) is recognized as a novel third-generation antiepileptic drug approved for the treatment of epilepsy. Emerging evidence has demonstrated that it has potentially better efficacy and tolerability than its analog, Levetiracetam (LEV). This,
Te-Yu Hung, Sheng-Nan Wu, Chin-Wei Huang
doaj +1 more source
Frontiers in Cellular Neuroscience, 2022 Implications of glia in the pathophysiology of epilepsy raise the question of how these cells besides neurons are responsive to antiseizure medications (ASMs).
Fatme Seval Ismail +5 more
doaj +1 more source
Креативная хирургия и онкология, 2023 Introduction. Epilepsy is a frequent complication in patients with malignant neoplasms of the brain. However, despite an extensive number of studies, anticonvulsants with antitumor activity have not been studied enough.
Y. Wang +6 more
doaj +1 more source